NDA 018123 · Hikma
Factrel
Gonadorelin Hydrochloride · Injection
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 19, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Sep 30, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,016
295 Phase 3, 104 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 1982 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- FACTREL · GONADORELIN HYDROCHLORIDE EQ 0.5MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
- FACTREL · GONADORELIN HYDROCHLORIDE EQ 0.1MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
- FACTREL · GONADORELIN HYDROCHLORIDE EQ 0.2MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Gonadorelin" as an intervention, any sponsor and status, largest first.
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerPivotal-lookingCompleted
ETOP IBCSG Partners FoundationResearch network
NCT00066690 · 3,066 participants · Start Dec 17, 2003 · Primary completion May 2014
Drug: Exemestane; Tamoxifen and 1 more · For: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma and 5 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Scottsdale, Arizona · 500 sites in all
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002651 · 3,040 participants · Start May 1995 · Primary completion Jun 2013
Drug: bicalutamide; goserelin acetate · For: Prostate Cancer
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 14 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Endometriosis.
Johnson N, Farquhar C · BMJ Clin Evid 2007 · Systematic Review
- Endometriosis.
Ferrero S, Remorgida V, Venturini PL · BMJ Clin Evid 2010 · Systematic Review
- Menorrhagia.
Duckitt K, Collins S · BMJ Clin Evid 2012 · Systematic Review
- Breast pain.
Bundred NJ · BMJ Clin Evid 2007 · Systematic Review
- Breast pain.
Goyal A · BMJ Clin Evid 2011 · Systematic Review
- Premenstrual syndrome.
Kwan I, Onwude JL · BMJ Clin Evid 2007 · Systematic Review
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.